Genocea Reports Fourth Quarter and Year-End 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Needham & Company Downgrades Genocea Biosciences (GNCA) to Hold
February 17, 2017 7:09 AM ESTNeedham & Company downgraded Genocea Biosciences (NASDAQ: GNCA) from Buy to Hold, saying uncertainty around the HSV2 program is a concern.
Analyst Alan Carr commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017.... More
Genocea Biosciences (GNCA) Misses Q4 EPS by 11c
February 16, 2017 7:36 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.56), $0.11 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $0, versus $0 reported last year.
Cash, cash equivalents and investments as of December 31, 2016 were $63.4 million compared to $75.5 million as of September 30, 2016.
For earnings... More
